Contact
Please use this form to send email to PR contact of this press release:
FDA Accepts BioCryst’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks
TO:
Please use this form to send email to PR contact of this press release:
FDA Accepts BioCryst’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks
TO: